Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070797 | 1.00 | HTT (0.50) | HTTKDM4EHPGDKMT2ATAS2R14 | |
| SCHEMBL23393372 | 0.91 | HTT (0.49) | HTTKDM4EHPGDKMT2ATAS2R14 | |
| SCHEMBL23393374 | 0.91 | HTT (0.49) | HTTKDM4EHPGDKMT2ATAS2R14 | |
| SCHEMBL21483587 | 0.84 | HTT (0.46) | HTTKDM4EHPGDKMT2ATAS2R14 | |
| SCHEMBL21483293 | 0.84 | MAPT (0.40) | KDM4EHPGDKMT2AALDH1A1MAPT | |
| SCHEMBL30070788 | 0.84 | MAPT (0.40) | KDM4EHPGDKMT2AALDH1A1MAPT | |
| SCHEMBL21483285 | 0.84 | ABCB1 (0.42) | HTTKMT2AMRGPRX4LRRK2PTGDR2 | |
| SCHEMBL30070808 | 0.84 | HTT (0.46) | HTTKDM4EHPGDKMT2ATAS2R14 | |
| SCHEMBL30070726 | 0.84 | ABCB1 (0.42) | HTTKMT2AMRGPRX4LRRK2PTGDR2 | |
| SCHEMBL21483438 | 0.83 | MAPT (0.47) | KDM4EHPGDKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155591-A1 | 2-(2,2-DIARYLETHYL)-CYCLIC AMINE DERIVATIVE OR SALT, SYNTHESIS THEREOF, AND APPLICATION AND COMPOSITION THEREOF | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2019196898-A1 | 2-(2,2-DIARYLETHYL)-CYCLIC AMINE DERIVATIVE OR SALT, SYNTHESIS THEREOF, AND APPLICATION AND COMPOSITION THEREOF | 中国科学院大连化学物理研究所 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155591-A1 | 2-(2,2-DIARYLETHYL)-CYCLIC AMINE DERIVATIVE OR SALT, SYNTHESIS THEREOF, AND APPLICATION AND COMPOSITION THEREOF | CHRNB2, ADRB2, CHRNB1 | HTT 3752/4885KDM4E 3872/4885HPGD 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.